Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | VP Corporate Controller | December 15, 2021 | December 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date December 15, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.75 · Expires 2031-12-15 | Direct | 15,000 |
Reported balance
After 2021-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-15 · Grant · Acquired 15,000 · Balance 15,000 F2: (2) Not applicable. F1: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date). |
Filing footnotes · ownership attribution and instrument terms
F1: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date).
F2: (2) Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 16:09 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001871604-21-000004 · wf-form4_163977535437475.xml · derivative · entry 1 Maranian Jeffrey R · CIK 0001871604 · VP Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-12-15 F2 · price: (2) Not applicable. F1 · derivative.exercise_date: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date). Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:19 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $5.28 | Not disclosed |
DisclosureSEC source: 0001871604-21-000002 · wf-form4_163701118201148.xml · derivative · entry 1 Maranian Jeffrey R · CIK 0001871604 · VP Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-11-11 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on November 11, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 11, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.